PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-4 (4)
 

Clipboard (0)
None
Journals
Year of Publication
Document Types
1.  13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus – Opinion of a German Team of Experts (Zurich 2013) 
Breast Care  2013;8(3):221-229.
Summary
The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. The panel in St. Gallen is composed of international experts from different countries. From a German perspective, it seems reasonable to interpret the voting results in the light of AGO-recommendations and S3-guidelines for everyday practice in Germany. Consequently, a team of eight breast cancer experts, of whom two are members of the international St. Gallen panel, commented on the voting results of the St. Gallen Consensus Conference (2013). The main topics at this year's St. Gallen conference were surgical issues of the breast and axilla, radio-therapeutic and systemic treatment options, and the clinical relevance of tumour biology. The clinical utility of multigene assays for supporting individual treatment decisions was also intensively discussed.
doi:10.1159/000351692
PMCID: PMC3728634  PMID: 24415975
St. Gallen Consensus; Early breast cancer; Adjuvant therapy; Multigene signatures; Targeted therapy
2.  Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer) 
Breast Care  2009;4(2):109-116.
Summary
A German working group of 23 breast cancer experts discussed the results from the vote at this year's St. Gallen Consensus Conference on Primary Therapy for Early Breast Cancer (March 11–14, 2009) and came up with some concrete recommendations for day-to-day therapeutic decisions in Germany. Due the fact that the concept of the St. Gallen Consensus Conference merely allows for a minimal consensus, the objective of the working group was to provide practice-related recommendations for day-to-day clinical decisions in Germany. One area of emphasis at St. Gallen was tumor biology as a starting point for reaching individual therapeutic decisions. Intensive discussion was necessary with respect to the clinical relevance of predictive and prognostic factors. A new addition to the area of systemic therapy was a first-ever discussion of the adjuvant administration of bisphosponates and the fact that therapy with trastuzumab in HER2 overexpressing breast cancer has been defined as the standard for neoadjuvant therapy. The value of taxanes as a component of (neo)adjuvant chemotherapy as well as the value of aromatase inhibitors for the endocrine adjuvant treatment of postmenopausal patients were affirmed.
doi:10.1159/000212164
PMCID: PMC2931071  PMID: 21049070
3.  Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer 
Breast Care  2008;3(5):317-324.
Summary
Five years of adjuvant tamoxifen treatment has been the gold standard for women with early hormone-responsive breast cancer. Results from two large phase III, adjuvant studies have indicated that the third-generation aro-matase inhibitors (AIs) letrozole and anastrozole offer greater protection against recurrence than tamoxifen in upfront substitution strategies in the first 5 years. Similarly, changeover to an AI (exemestane or anastrozole) after 2-3 years of tamoxifen has been more efficient to prevent recurrence than 5 years of tamoxifen. Most early breast cancer recurrences occur 5 or more years after surgery. Letrozole has been shown to offer greater protection against recurrence than placebo in the 5 years after a standard course of tamoxifen. The optimal adjuvant use (duration and sequencing) of AIs requires further investigation. Safety implications of treatment with these AIs for 5 years or more are closely monitored. The anticipated effects of estrogen deprivation on bone health may be treatable with bisphosphonates. Effects on the cardiovascular system, and other estrogen-sensitive systems such as the central nervous system, are currently examined. The AIs letrozole, anastrozole, and ex-emestane have recently replaced tamoxifen as the recommended adjuvant endocrine therapy, on the basis of greater efficacy and better tolerability.
doi:10.1159/000155548
PMCID: PMC2931103  PMID: 20824026
Early breast cancer; Aromatase inhibitors; Letrozole; Anastrozole; Exemestane; Tamoxifen
4.  Adjuvant Consensus: A Breast Cancer Patient Web Tool 
Breast Care  2008;3(2):114-117.
Summary
The new web tool Adjuvant Consensus gives the user access to the most recent information on how world leading experts suggest to treat a specific breast cancer with systemic therapy. By entering tumor characteristics, age, and menopausal status, the user can find out what experts and national guidelines suggest for this specific tumor. The basis for the suggested treatment options and guidelines are coming from 2 world leading resources: They reflect the reached expert consensus on the implications of evidence for patient treatment selection at the world leading consensus conference on adjuvant therapy held regularly in St. Gallen, and the ‘Clinical Practice Guidelines in Oncology’ for breast cancer published in the US by the National Cancer Center Network in January 2007. The calculated treatment options include the suggested systemic treatment — chemotherapy, hormonal therapy, and antibody therapy, alone or in combination — and the duration and sequence of therapy. Furthermore, the user can find information on the mode of action and important side effects of the different drugs.
doi:10.1159/000126737
PMCID: PMC2931085  PMID: 21373214
Breast cancer; Internet; Counseling

Results 1-4 (4)